The review found no eligible studies for this question.
The review found no eligible studies for this question.
Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).
Early systemic postnatal corticosteroids leads to lower mortality or BPD at 36 weeks' PMA compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids leads to higher gastrointestinal perforation during primary hospitalisation compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids leads to higher cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids showed no clear difference in mortality or cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
Summary of findings: intranasal steroids showed no clear difference in hearing loss (Audiometry failing) [9 months]2 compared with control (moderate certainty).
Summary of findings: intranasal steroids showed no clear difference in OME resolution at short‐term compared with control (moderate certainty).
Summary of findings: intranasal steroids showed no clear difference in OME resolution at intermediate‐term compared with control (moderate certainty).
Summary of findings: intranasal steroids probably leads to lower OME resolution at long‐term compared with control (moderate certainty).
The review found no eligible studies for this question.
Summary of findings: intranasal steroids showed no clear difference in adverse effects [3 months] compared with control (low certainty).
Inhaled corticosteroids plus standard care showed no clear difference in all‐cause mortality compared with standard care (with or without placebo) (low certainty).
Inhaled corticosteroids plus standard care probably leads to lower admission to hospital or death compared with standard care (with or without placebo) (moderate certainty).
Inhaled corticosteroids plus standard care probably leads to higher symptom resolution: all initial symptoms resolved at day 14 compared with standard care (with or without placebo) (moderate certainty).
Inhaled corticosteroids plus standard care showed no clear difference in symptom resolution: duration to symptoms resolved compared with standard care (with or without placebo) (low certainty).
It is very uncertain whether inhaled corticosteroids plus standard care changes serious adverse events compared with standard care (with or without placebo) (very low certainty).